Dapagliflozin and Changes in Metabolic Syndrome in Patients With Type 2 Diabetes: A DECLARE TIMI 58 Sub-Analysis

被引：0
|
作者：
Moura, Filipe A.
Raz, Itamar
Cahn, Avivit
Goodrich, Erica
Bhatt, Deepak L.
Leiter, Lawrence A.
Wilding, John
Gause-nilsson, Ingrid A.
Mosenzon, Ofri
Sabatine, Marc S.
Wiviott, Stephen D.
机构：
来源：
CIRCULATION | 2021年 / 144卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A13182
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial
    Schechter, Meir
    Wiviott, Stephen
    Raz, Itamar
    Goodrich, Erica L.
    Rozenberg, Aliza
    Yanuv, Ilan
    Murphy, Sabina A.
    Zelniker, Thomas A.
    Fredriksson, Martin
    Johansson, Peter A.
    Leiter, Lawrence A.
    Bhatt, Deepak L.
    McGuire, Darren K.
    Wilding, John P. H.
    Gause-Nilsson, Ingrid A. M.
    Cahn, Avivit
    Langkilde, Anna Maria
    Sabatine, Marc S.
    Mosenzon, Ofri
    LANCET DIABETES & ENDOCRINOLOGY, 2023, 11 (04): : 233 - 241
  • [22] Dapagliflozin reduces the risk of hospitalization in patients with type 2 diabetesNew results from the DECLARE-TIMI 58 study
    Schamarek, Imke
    DIABETOLOGIE, 2023, 19 (05): : 702 - 704
  • [23] The Efficacy and Safety of Dapagliflozin in Women and Men With Type 2 Diabetes Mellitus: Insights From The DECLARE-TIMI 58 Trial
    O'Donoghue, Michelle L.
    Kato, Eri T.
    Mosenzon, Ofri
    Murphy, Sabina A.
    Cahn, Avivit
    Marmolejo, Marisol H.
    Tankova, Tsvetalina
    Smahelova, Alena
    Merlini, Piera A.
    Gause-Nilsson, Ingrid A.
    Langkilde, Anna Maria
    McGuire, Darren K. K.
    Wilding, John
    Leiter, Lawrence A.
    Bhatt, Deepak L.
    Raz, Itamar
    Sabatine, Marc S.
    Wiviott, Stephen D.
    CIRCULATION, 2019, 140
  • [24] Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial
    Furtado, Remo H. M.
    Raz, Itamar
    Goodrich, Erica L.
    Murphy, Sabina A.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Aylward, Philip
    Dalby, Anthony J.
    Dellborg, Mikael
    Dimulescu, Doina
    Nicolau, Jose C.
    Oude Ophuis, Anthonius J. M.
    Cahn, Avivit
    Mosenzon, Ofri
    Gause-Nilsson, Ingrid
    Langkilde, Anna Maria
    Sabatine, Marc S.
    Wiviott, Stephen D.
    CIRCULATION, 2022, 145 (21) : 1581 - 1591
  • [25] Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study
    Cahn, Avivit
    Mosenzon, Ofri
    Wiviott, Stephen D.
    Rozenberg, Aliza
    Yanuv, Ilan
    Goodrich, Erica L.
    Murphy, Sabina A.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Gause-Nilsson, Ingrid A. M.
    Fredriksson, Martin
    Johansson, Peter A.
    Langkilde, Anna Maria
    Sabatine, Marc S.
    Raz, Itamar
    DIABETES CARE, 2020, 43 (02) : 468 - 475
  • [26] MEDIATION ANALYSIS FOR DAPAGLIFLOZIN AND THE REDUCTION IN HOSPITALIZATION FOR HEART FAILURE IN DECLARE-TIMI 58
    Berg, David
    Wiviott, Stephen
    Goodrich, Erica
    Murphy, Sabina
    Mosenzon, Ofri
    Bhatt, Deepak
    Cahn, Avivit
    Leiter, Lawrence
    McGuire, Darren
    Wilding, John
    Gause-Nilsson, Ingrid
    Hammarstedt, Ann
    Karlsson, Cecilia
    Johansson, Peter
    Langkilde, Anna-Maria
    Raz, Itamar
    Sabatine, Marc
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 869 - 869
  • [27] Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58
    Zelniker, T. A.
    Raz, I.
    Mosenzon, O.
    Dwyer, J. P.
    Heerspink, H. J. L.
    Cahn, A.
    Im, K.
    Bhatt, D. L.
    Leiter, L. A.
    McGuire, D. K.
    Wilding, J. P. H.
    Gause-Nilsson, I. A. M.
    Langkilde, A. M.
    Sabatine, M. S.
    Wiviott, S. D.
    EUROPEAN HEART JOURNAL, 2019, 40 : 54 - 54
  • [28] Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58
    Zelniker, T.
    Raz, I.
    Mosenzon, O.
    Dwyer, J.
    Heerspink, H.
    Cahn, A.
    Im, K.
    Deepak, B.
    Leiter, L.
    McGuire, D.
    Wilding, J.
    Gause-Nilsson, I.
    Langkilde, A. M.
    Sabatine, M.
    Wiviott, S.
    WIENER KLINISCHE WOCHENSCHRIFT, 2020, 132 : S175 - S175
  • [29] Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study
    Norhammar, Anna
    Bodegard, Johan
    Nystrom, Thomas
    Thuresson, Marcus
    Nathanson, David
    Eriksson, Jan W.
    DIABETES OBESITY & METABOLISM, 2019, 21 (05): : 1136 - 1145
  • [30] Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial (vol 7, pg 606, 2019)
    Mosenzon, O.
    Wiviott, S. D.
    Cahn, A.
    LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (08): : E20 - E20
12345